(Q28219069)

English

Incidence and management of bevacizumab-related toxicities in colorectal cancer

scientific article (publication date: July 2006)

In more languages

edit

Statements

0 references

1 reference

Europe PubMed Central

title

Incidence and management of bevacizumab-related toxicities in colorectal cancer (English)

0 references

1 reference

1 reference

1 reference

M Wasif Saif

1

0 references

Ranee Mehra

series ordinal

2

0 references

language of work or name

English

0 references

publication date

July 2006

0 references

published in

Expert Opinion on Drug Safety

0 references

volume

5

0 references

issue

4

0 references

page(s)

553-66

0 references

cites work

Angiogenesis in cancer and other diseases

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517/14740338.5.4.553

retrieved

21 April 2017

The biology of VEGF and its receptors

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517/14740338.5.4.553

retrieved

21 April 2017

Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517/14740338.5.4.553

retrieved

21 April 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517/14740338.5.4.553

retrieved

21 April 2017

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 April 2017

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 April 2017

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 April 2017

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 April 2017

Angiogenesis-dependent diseases and angiogenesis therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 January 2018

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 January 2018

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 January 2018

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 January 2018

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 January 2018

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 January 2018

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 January 2018

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 January 2018

Angiogenic growth factors and hypertension

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 January 2018

Role of vascular endothelial growth factor in the regulation of angiogenesis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.5.4.553

retrieved

21 January 2018

Identifiers

DOI

10.1517/14740338.5.4.553

0 references

PubMed ID

16774493

0 references

(Q28219069)

Incidence and management of bevacizumab-related toxicities in colorectal cancer

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)